Annual Reportable Changes: What to Include in Your NDA/ANDA Annual Report
NDA and ANDA holders must submit an annual report to FDA within 60 days of the application's approval anniversary, per 21 CFR 314.81(b)(2). The annual report includes distribution data, labeling, minor CMC changes (SUPAC Level 1), nonclinical and clinical study summaries, adverse event report references, and post-marketing commitment status updates. The annual report is the least burdensome reporting mechanism for post-approval changes, covering changes with minimal potential to affect product quality.
Key Takeaways
Key Takeaways
- Annual reports are due within 60 days of the NDA/ANDA approval anniversary under 21 CFR 314.81(b)(2) and are mandatory even if no changes occurred.
- The annual report covers SUPAC Level 1 (minimal-impact) CMC changes, distribution data, current labeling, and PMR/PMC status updates.
- Failure to file can result in Warning Letters, increased FDA scrutiny, or in extreme cases, withdrawal proceedings.
- The annual report is distinct from periodic adverse drug experience reports (PADERs), REMS assessments, and PSURs/PBRERs, each with separate filing schedules.
Annual Report Requirements: The Regulatory Framework
Legal Basis
The annual report obligation is established by 21 CFR 314.81(b)(2), which requires every NDA and ANDA holder to submit an annual report within 60 days of the anniversary date of the application's approval. This is a mandatory obligation — failure to submit the annual report can result in FDA enforcement action.
The annual report serves dual purposes:
- It is a compliance reporting mechanism, providing FDA with ongoing information about the marketed product
- It is a reporting vehicle for minor post-approval changes that do not warrant individual supplement filings
Due Date Calculation
The annual report covers the period from the anniversary date of approval to the next anniversary date. It is due within 60 days of the end of the reporting period.
Example:
- NDA approval date: June 15, 2024
- First annual report period: June 15, 2024 - June 14, 2025
- First annual report due: August 14, 2025 (60 days after June 15, 2025)
If the due date falls on a weekend or federal holiday, the report is due on the next business day.
Who Must File
Every holder of an approved NDA, ANDA, or BLA must file annual reports. This includes:
- Innovator (NDA) holders
- Generic (ANDA) holders
- Biologics (BLA) holders (under 21 CFR 600.81)
- Holders of approved supplements (the parent application's annual report covers all supplements)
If an application is transferred to a new holder, the new holder assumes the annual report obligation.
Content of the Annual Report
Required Sections Under 21 CFR 314.81(b)(2)
The regulation specifies the following content for the annual report:
| Section | CFR Reference | Content Required |
|---|---|---|
| Summary | 314.81(b)(2) | Brief summary of significant new information affecting safety, effectiveness, or labeling |
| Distribution data | 314.81(b)(2)(i) | Quantity distributed domestically and quantity distributed for foreign use |
| Labeling | 314.81(b)(2)(ii) | Currently used professional labeling, patient labeling, and any labeling changes during the year |
| Chemistry, manufacturing, and controls | 314.81(b)(2)(iii) | Reports of CMC changes filed as annual reportable changes |
| Nonclinical laboratory studies | 314.81(b)(2)(iv) | Copies or summaries of nonclinical studies completed or learned of during the year |
| Clinical data | 314.81(b)(2)(v) | Published clinical trials and unpublished studies involving the drug |
| Status of post-marketing commitments | 314.81(b)(2)(vii) | Current status of all PMRs and PMCs |
| Log of outstanding regulatory business | 314.81(b)(2) | Pending supplements, unanswered FDA correspondence |
Distribution Data (Section i)
The annual report must include:
| Data Point | Details |
|---|---|
| Domestic distribution | Total quantity of drug distributed in the United States during the reporting period |
| Foreign distribution | Total quantity distributed for foreign use (export) |
| Unit of measure | Must be in dosage units (e.g., tablets, capsules, vials) or weight/volume |
Important notes on distribution data:
- Distribution data means quantity shipped or sold, not quantity manufactured
- FDA uses distribution data to assess market penetration, calculate adverse event reporting rates, and plan inspections
- Significant changes in distribution volume may trigger FDA inquiries
- If the product was not distributed during the reporting period, state this explicitly
Labeling (Section ii)
Include in the annual report:
| Item | Requirement |
|---|---|
| Current prescribing information | Full text of the currently approved labeling |
| Patient labeling | Current Medication Guide, Patient Package Insert, or Instructions for Use (if applicable) |
| Labeling changes | Any labeling changes made during the reporting period, with dates and reference to the supplement under which the change was made |
| Promotional labeling | Not required in the annual report (but tracked separately under 21 CFR 314.81(b)(3)(i)) |
Chemistry, Manufacturing, and Controls (Section iii)
This is the section where annual reportable changes are documented. Per 21 CFR 314.81(b)(2)(iii), the applicant must include:
A report of any change to the drug product or its manufacturing process that has been made during the reporting period and not reported as a supplement.
This means all SUPAC Level 1 changes and other minor CMC changes that were implemented during the year under the Annual Report reporting category.
For each change, the report should include:
| Element | Content |
|---|---|
| Description of change | What specifically changed, from what baseline to what new state |
| Date of implementation | When the change was put into effect |
| Rationale | Why the change qualifies as annual reportable (reference SUPAC level or 314.70 criteria) |
| Supporting data | Relevant test results (batch dissolution, stability initiation, release testing) |
| Affected sections | Which sections of the approved application are affected |
Annual Reportable CMC Changes in Detail
SUPAC Level 1 Changes
The SUPAC guidances define Level 1 changes as those with minimal potential to adversely affect product quality. These are the primary CMC changes reported in the annual report.
Component and Composition (SUPAC-IR Level 1)
| Change | Details | Supporting Data |
|---|---|---|
| Excipient quantity change within +/-5% of total weight | Example: Changing lactose from 30% to 31% of total tablet weight | Release testing on 1 post-change batch |
| Total additive effect of all excipient changes within +/-5% | Cumulative changes to multiple excipients within the total threshold | Release testing on 1 post-change batch |
| Deletion of non-functional colorant or flavoring | Removing a lake dye from a tablet coating | Release testing showing no impact on stability |
Data requirement: One batch tested at release and placed on long-term stability per ICH Q1A(R2). Single-point dissolution in the approved medium.
Manufacturing Site (SUPAC-IR Level 1)
| Change | Details | Supporting Data |
|---|---|---|
| Change within a single facility | Moving from one production room to another within the same building | Release testing on 1 batch |
| Same equipment, SOPs, environmental controls, and personnel | No changes to how the product is manufactured, only where within the facility | Dissolution (single point) |
Scale/Batch Size (SUPAC-IR Level 1)
| Change | Details | Supporting Data |
|---|---|---|
| Change up to and including 10x the pilot/biobatch size | Scaling from a 50 kg biobatch to a 500 kg commercial batch | Release testing, single-point dissolution |
| Scale-down within the approved range | Reducing batch size within previously validated range | Release testing |
Manufacturing Process (SUPAC-IR Level 1)
| Change | Details | Supporting Data |
|---|---|---|
| Operating within approved ranges | Adjusting blending speed within the validated range listed in the application | Batch record documentation |
| Equipment adjustments within same type and model | Replacement of wear parts, routine maintenance | Release testing |
Other Annual Reportable Changes (Non-SUPAC)
| Change | Description | Supporting Data |
|---|---|---|
| Imprinting change | Changing tablet deboss code or capsule imprint | Visual inspection confirming correct imprinting |
| Addition of alternative analytical method (same technology) | Adding a second HPLC column that can be used as backup | Method validation data showing equivalence |
| Container closure change (same material, negligible impact) | Changing bottle capacity (e.g., 100-count to 500-count) with same resin and closure type | Stability data confirming no impact |
| Reprocessing within approved parameters | Documenting reprocessing procedure already described in the approved application | Batch records showing process was within approved parameters |
| Editorial batch record changes | Clarifying instructions without changing the manufacturing process | Updated batch record excerpts |
| Stability protocol updates | Changing stability testing frequency or adding new timepoints | Updated stability protocol |
What Does NOT Belong in the Annual Report
Not all minor changes qualify for the Annual Report. The following require supplement filings:
| Change | Why Not Annual Report | Correct Filing |
|---|---|---|
| Tightening specification limits | Moderate impact (SUPAC Level 2) | CBE-30 |
| New analytical method using different technology | Moderate impact | CBE-30 |
| Manufacturing site change to different facility | Moderate impact (SUPAC Level 2) | CBE-30 |
| Any relaxation of specifications | Substantial impact | PAS |
| Formulation change beyond SUPAC Level 1 range | Beyond minimal impact | CBE-30 or PAS |
| Safety labeling change | Requires prompt reporting | CBE-0 |
The Cumulative Change Problem
A common mistake is reporting multiple changes as individual Level 1 Annual Report changes when their cumulative effect exceeds the Level 1 threshold. For example:
- Change 1: Increase excipient A from 5% to 5.4% (+0.4%, within +/-5%)
- Change 2: Decrease excipient B from 10% to 9.7% (-0.3%, within +/-5%)
- Change 3: Increase excipient C from 3% to 3.2% (+0.2%, within +/-5%)
Each individual change is within the +/-5% range. But SUPAC-IR requires that the total additive effect of all excipient changes remain within +/-5%. If these changes are cumulative since the last supplement, the total change may exceed the threshold, requiring a CBE-30.
Applicants must track cumulative changes against the approved baseline (the most recently approved formulation, as documented in the approved supplement or original application), not against the formulation at the time of the last annual report.
Nonclinical and Clinical Data Sections
Nonclinical Laboratory Studies (Section iv)
The annual report must include copies of or references to unpublished reports and summaries of published reports of nonclinical studies completed or learned of during the reporting period. This includes:
| Study Type | What to Include |
|---|---|
| Toxicology studies | Summaries of completed long-term toxicology studies |
| Carcinogenicity studies | Summaries or interim reports |
| Reproductive toxicology | Developmental and reproductive toxicity data |
| Safety pharmacology | New safety pharmacology data |
If no new nonclinical data exists, state this explicitly.
Clinical Data (Section v)
The annual report must include:
| Data Type | What to Include |
|---|---|
| Published studies | Citations to published clinical trials involving the drug product |
| Unpublished studies | Summaries of completed unpublished clinical studies conducted by or on behalf of the applicant |
| Post-marketing studies | Status and results of Phase IV or post-marketing studies |
| Literature reports | Significant case reports or clinical analyses from the literature |
Distinguishing Clinical Data in Annual Report vs. Adverse Event Reports
Clinical data in the annual report section covers studies and publications, not individual adverse event case reports. Adverse event reporting obligations are separate (21 CFR 314.80) and include 15-day expedited reports and periodic adverse drug experience reports (PADERs). The annual report should reference these reports but does not duplicate them.
Post-Marketing Commitment/Requirement Status (Section vii)
Required Reporting
Per 21 CFR 314.81(b)(2)(vii), the applicant must provide a status update for each PMR and PMC associated with the application. The report must include:
| Element | Content |
|---|---|
| PMR/PMC identifier | FDA-assigned identifier for the commitment/requirement |
| Description | Brief description of the study or trial |
| Original timeline | Milestones and expected completion dates from the original agreement |
| Current status | Pending, Ongoing, Submitted, Fulfilled, Released, Delayed, Terminated |
| Progress update | Description of activities completed during the reporting period |
| Revised timeline | If delayed, updated milestones and projected completion dates |
| Reason for delay | If delayed, explanation of the delay and corrective actions |
Status Categories (per FDA Guidance)
| Status | Definition | Applicant Action Required |
|---|---|---|
| Pending | Not yet initiated | Provide expected initiation date |
| Ongoing | Actively in progress | Provide progress update and expected completion |
| Submitted | Final report submitted to FDA | Reference the submission date and sequence number |
| Fulfilled | FDA has reviewed and accepted results | No further action for this commitment |
| Released | FDA has released the applicant from the obligation | No further action |
| Delayed | Behind original schedule | Provide explanation and revised timeline |
| Terminated | Study stopped before completion | Provide justification for termination |
IND Annual Report vs. NDA Annual Report
Key Differences
These are different regulatory requirements that applicants sometimes confuse:
| Feature | IND Annual Report | NDA/ANDA Annual Report |
|---|---|---|
| Regulatory basis | 21 CFR 312.33 | 21 CFR 314.81(b)(2) |
| When required | During investigational phase | After approval |
| Due date | Within 60 days of IND anniversary | Within 60 days of NDA/ANDA approval anniversary |
| Content focus | Clinical trial progress, safety data, protocol amendments | Distribution, labeling, CMC changes, PMR/PMC status |
| CMC changes | Changes to drug substance/product used in trials | Post-approval manufacturing changes |
| Safety reporting | Summarizes IND safety reports filed during the year | References PADERs and 15-day reports |
| Distribution data | Not required (investigational use) | Required (commercial distribution) |
| Ongoing once NDA approved? | IND annual report stops when NDA is approved; NDA annual report begins | NDA annual report begins |
Transition from IND to NDA Reporting
When an NDA is approved:
- The IND annual report obligation ceases (though the IND remains active unless explicitly withdrawn)
- The NDA annual report obligation begins on the approval date
- The first NDA annual report is due within 60 days of the first anniversary of approval
Filing and Formatting
eCTD Submission
Annual reports are submitted as eCTD sequences:
| Element | Specification |
|---|---|
| Submission type | Annual Report |
| Sequence number | Next sequential number in the application lifecycle |
| Module 1 content | Cover letter, annual report document |
| Affected modules | Update Module 3 sections for CMC changes, Module 1 for labeling |
| Lifecycle operations | Use appropriate operations (new, replace) for updated sections |
Structure of the Annual Report Document
The annual report itself is typically a single document within the eCTD sequence, organized according to the sections specified in 21 CFR 314.81(b)(2):
Multi-Strength/Multi-Form Products
If an NDA covers multiple strengths or dosage forms, a single annual report covers all strengths and forms under that application number. CMC changes that affect only one strength must be clearly identified as such.
Common Deficiencies in Annual Reports
| Deficiency | Description | Prevention |
|---|---|---|
| Late submission | Filed more than 60 days after anniversary | Calendar the due date immediately upon approval |
| Missing distribution data | No quantities reported | Track distribution throughout the year |
| Incomplete CMC change documentation | Changes implemented but not documented in the report | Maintain a log of all annual reportable changes throughout the year |
| Missing PMR/PMC status | Status updates for commitments omitted | Review PMR/PMC list before preparing annual report |
| Missing labeling | Current labeling not included | Include complete current labeling with every annual report |
| No statement when sections are negative | Silence on nonclinical or clinical data | Explicitly state "No new [nonclinical/clinical] data during this reporting period" |
| Cumulative changes exceeding Level 1 | Multiple Level 1 changes that collectively exceed threshold | Track cumulative changes against the approved baseline |
Enforcement Consequences
What Happens If You Do Not File
FDA takes annual report non-compliance seriously. Potential consequences include:
| Action | Trigger | Impact |
|---|---|---|
| Untitled letter or Warning Letter | Missed or significantly late annual report | Requires corrective action |
| Compliance program flag | Pattern of late or deficient annual reports | Increased FDA scrutiny |
| GMP inspection focus area | Missing annual report information | Inspectors may review changes not reported |
| Withdrawal proceedings | Extreme non-compliance, combined with other violations | Loss of approved application |
In practice, FDA most commonly addresses annual report deficiencies through Warning Letters that cite failure to comply with 21 CFR 314.81(b)(2). These letters typically require the applicant to submit the overdue annual report and implement procedures to prevent future lapses.
Key Regulatory References
| Reference | Description |
|---|---|
| 21 CFR 314.81(b)(2) | NDA/ANDA annual report requirements |
| 21 CFR 314.70(e) | Annual reportable changes (minimal potential impact) |
| 21 CFR 600.81 | Annual report requirements for biologics |
| 21 CFR 312.33 | IND annual report requirements |
| SUPAC-IR (Nov 1995) | Level 1 changes for immediate-release oral solids |
| SUPAC-MR (Sep 1997) | Level 1 changes for modified-release oral solids |
| SUPAC-SS (May 1997) | Level 1 changes for nonsterile semisolids |
| FDA Guidance: Changes to Approved NDA/ANDA (Apr 2004) | General reporting category guidance |
| ICH Q1A(R2) | Stability testing requirements for long-term studies |
| FDA Guidance: Reporting Format for Annual Reports (Sep 1995) | Formatting guidance (older but still referenced) |
References
Yes. The annual report can be submitted before the due date. Some applicants submit the annual report shortly after the anniversary date to avoid the 60-day deadline. There is no requirement to wait until the end of the 60-day window.